Logo image of GERN

GERON CORP (GERN) Stock Fundamental Analysis

NASDAQ:GERN - Nasdaq - US3741631036 - Common Stock

2.99  +0.03 (+1.01%)

After market: 2.9999 +0.01 (+0.33%)

Fundamental Rating

2

Overall GERN gets a fundamental rating of 2 out of 10. We evaluated GERN against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of GERN have multiple concerns. GERN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GERN had negative earnings in the past year.
GERN had a negative operating cash flow in the past year.
GERN had negative earnings in each of the past 5 years.
GERN had a negative operating cash flow in each of the past 5 years.
GERN Yearly Net Income VS EBIT VS OCF VS FCFGERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

GERN has a Return On Assets (-45.22%) which is comparable to the rest of the industry.
GERN's Return On Equity of -68.83% is in line compared to the rest of the industry. GERN outperforms 56.64% of its industry peers.
Industry RankSector Rank
ROA -45.22%
ROE -68.83%
ROIC N/A
ROA(3y)-57.52%
ROA(5y)-48.38%
ROE(3y)-114.5%
ROE(5y)-86.01%
ROIC(3y)N/A
ROIC(5y)N/A
GERN Yearly ROA, ROE, ROICGERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GERN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GERN Yearly Profit, Operating, Gross MarginsGERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K

More info and screens

3

2. Health

2.1 Basic Checks

GERN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GERN has more shares outstanding
GERN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for GERN has been reduced compared to a year ago.
GERN Yearly Shares OutstandingGERN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M
GERN Yearly Total Debt VS Total AssetsGERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

GERN has an Altman-Z score of 0.76. This is a bad value and indicates that GERN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of GERN (0.76) is better than 66.19% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that GERN is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.04, GERN is not doing good in the industry: 61.42% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 0.76
ROIC/WACCN/A
WACC11.01%
GERN Yearly LT Debt VS Equity VS FCFGERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

GERN has a Current Ratio of 2.89. This indicates that GERN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.89, GERN is not doing good in the industry: 67.26% of the companies in the same industry are doing better.
A Quick Ratio of 2.74 indicates that GERN has no problem at all paying its short term obligations.
With a Quick ratio value of 2.74, GERN is not doing good in the industry: 66.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 2.74
GERN Yearly Current Assets VS Current LiabilitesGERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.88% over the past year.
The Revenue has grown by 9409.68% in the past year. This is a very strong growth!
GERN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -26.03% yearly.
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)9409.68%
Revenue growth 3Y-1.76%
Revenue growth 5Y-26.03%
Sales Q2Q%17138.41%

3.2 Future

Based on estimates for the next years, GERN will show a very strong growth in Earnings Per Share. The EPS will grow by 30.55% on average per year.
GERN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 429.91% yearly.
EPS Next Y11.99%
EPS Next 2Y31.82%
EPS Next 3Y37.01%
EPS Next 5Y30.55%
Revenue Next Year25937.1%
Revenue Next 2Y3090.23%
Revenue Next 3Y1133.92%
Revenue Next 5Y429.91%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GERN Yearly Revenue VS EstimatesGERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
GERN Yearly EPS VS EstimatesGERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GERN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GERN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GERN Price Earnings VS Forward Price EarningsGERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GERN Per share dataGERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as GERN's earnings are expected to grow with 37.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.82%
EPS Next 3Y37.01%

More info and screens

0

5. Dividend

5.1 Amount

GERN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GERON CORP

NASDAQ:GERN (1/22/2025, 8:27:00 PM)

After market: 2.9999 +0.01 (+0.33%)

2.99

+0.03 (+1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners76.49%
Inst Owner Change0.05%
Ins Owners0.09%
Ins Owner Change-0.24%
Market Cap1.81B
Analysts85.33
Price Target7.76 (159.53%)
Short Float %10.77%
Short Ratio5.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.57%
Min EPS beat(2)5.99%
Max EPS beat(2)53.15%
EPS beat(4)4
Avg EPS beat(4)21.2%
Min EPS beat(4)5.99%
Max EPS beat(4)53.15%
EPS beat(8)7
Avg EPS beat(8)19.01%
EPS beat(12)9
Avg EPS beat(12)14.37%
EPS beat(16)10
Avg EPS beat(16)10.57%
Revenue beat(2)2
Avg Revenue beat(2)130.18%
Min Revenue beat(2)45.76%
Max Revenue beat(2)214.6%
Revenue beat(4)3
Avg Revenue beat(4)324.94%
Min Revenue beat(4)-66.74%
Max Revenue beat(4)1106.15%
Revenue beat(8)4
Avg Revenue beat(8)165.01%
Revenue beat(12)7
Avg Revenue beat(12)255.48%
Revenue beat(16)10
Avg Revenue beat(16)211.66%
PT rev (1m)2.16%
PT rev (3m)4.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.81%
EPS NY rev (1m)0%
EPS NY rev (3m)18.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.65%
Revenue NY rev (1m)-1.69%
Revenue NY rev (3m)32.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 61.31
P/FCF N/A
P/OCF N/A
P/B 6.18
P/tB 6.18
EV/EBITDA N/A
EPS(TTM)-0.32
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0.05
BVpS0.48
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.22%
ROE -68.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.52%
ROA(5y)-48.38%
ROE(3y)-114.5%
ROE(5y)-86.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 170.74%
Cap/Sales 2.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 2.74
Altman-Z 0.76
F-Score3
WACC11.01%
ROIC/WACCN/A
Cap/Depr(3y)143.84%
Cap/Depr(5y)272.97%
Cap/Sales(3y)145.66%
Cap/Sales(5y)137.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y11.99%
EPS Next 2Y31.82%
EPS Next 3Y37.01%
EPS Next 5Y30.55%
Revenue 1Y (TTM)9409.68%
Revenue growth 3Y-1.76%
Revenue growth 5Y-26.03%
Sales Q2Q%17138.41%
Revenue Next Year25937.1%
Revenue Next 2Y3090.23%
Revenue Next 3Y1133.92%
Revenue Next 5Y429.91%
EBIT growth 1Y-14.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.25%
EBIT Next 3Y35.74%
EBIT Next 5YN/A
FCF growth 1Y-88.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-88.52%
OCF growth 3YN/A
OCF growth 5YN/A